Actively Recruiting
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Led by Novartis Pharmaceuticals · Updated on 2025-12-24
160
Participants Needed
14
Research Sites
211 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine medical care setting, as compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS, which includes glatiramer acetate, interferons, teriflunomide, or dimethyl fumarate)
CONDITIONS
Official Title
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent must be obtained before participating in the study.
- Diagnosis of Relapsing Multiple Sclerosis (RMS) according to McDonald Criteria (2017).
- Less than 5 years since the first MS symptom before starting ofatumumab.
- Treatment with ofatumumab for at least 3 months but not longer than 6 months before study inclusion.
- Ofatumumab treatment aligned with European Product Information for Kesimpta.
- At least one brain MRI scan performed at least 3 months after starting ofatumumab or planned within 31 days after study inclusion.
- Willingness and ability to complete study assessments, including patient-reported outcome questionnaires.
You will not qualify if you...
- Use of investigational drugs during the study, or within specified time frames before starting ofatumumab.
- Currently pregnant, breastfeeding, or intending to become pregnant during the study period.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Novartis Investigative Site
Alexandroupoli, Greece, 681 00
Actively Recruiting
2
Novartis Investigative Site
Athens, Greece, 115 21
Actively Recruiting
3
Novartis Investigative Site
Athens, Greece, 115 25
Actively Recruiting
4
Novartis Investigative Site
Athens, Greece, 115 27
Actively Recruiting
5
Novartis Investigative Site
Athens, Greece, 115 28
Actively Recruiting
6
Novartis Investigative Site
Athens, Greece, 145 61
Active, Not Recruiting
7
Novartis Investigative Site
Athens, Greece, 185 47
Actively Recruiting
8
Novartis Investigative Site
Chaïdári, Greece, 124 62
Actively Recruiting
9
Novartis Investigative Site
Crete Heraklion, Greece, 714 09
Actively Recruiting
10
Novartis Investigative Site
Ioannina, Greece, 455 00
Actively Recruiting
11
Novartis Investigative Site
Larissa, Greece, 411 10
Actively Recruiting
12
Novartis Investigative Site
Pátrai, Greece, 265 04
Actively Recruiting
13
Novartis Investigative Site
Thessaloniki, Greece, 53246
Actively Recruiting
14
Novartis Investigative Site
Thessaloniki, Greece, GR 54636
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here